170 related articles for article (PubMed ID: 8840843)
1. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study.
Cairns JA; Gill J; Morton B; Roberts R; Gent M; Hirsh J; Holder D; Finnie K; Marquis JF; Naqvi S; Cohen E
Circulation; 1996 Oct; 94(7):1553-60. PubMed ID: 8840843
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
Karsch KR; Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia EJ; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R
J Am Coll Cardiol; 1996 Nov; 28(6):1437-43. PubMed ID: 8917255
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty.
Grassman ED; Leya F; Fareed J; Lewis BE; Bacher P; Loeb HS; Moran JF
J Invasive Cardiol; 2001 Nov; 13(11):723-8. PubMed ID: 11689712
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty.
Bairati I; Roy L; Meyer F
Circulation; 1992 Mar; 85(3):950-6. PubMed ID: 1537131
[TBL] [Abstract][Full Text] [Related]
5. A prospective, randomized, and double-blind trial on the effect of fish oil on the incidence of restenosis following PTCA.
Franzen D; Schannwell M; Oette K; Höpp HW
Cathet Cardiovasc Diagn; 1993 Apr; 28(4):301-10. PubMed ID: 8462079
[TBL] [Abstract][Full Text] [Related]
6. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.
Lablanche JM; McFadden EP; Meneveau N; Lusson JR; Bertrand B; Metzger JP; Legrand V; Grollier G; Macaya C; de Bruyne B; Vahanian A; Grentzinger A; Masquet C; Wolf JE; Tobelem G; Fontecave S; Vacheron A; d'Azemar P; Bertrand ME
Circulation; 1997 Nov; 96(10):3396-402. PubMed ID: 9396433
[TBL] [Abstract][Full Text] [Related]
7. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty.
Reis GJ; Boucher TM; Sipperly ME; Silverman DI; McCabe CH; Baim DS; Sacks FM; Grossman W; Pasternak RC
Lancet; 1989 Jul; 2(8656):177-81. PubMed ID: 2568519
[TBL] [Abstract][Full Text] [Related]
8. [Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia E; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R; Karsch KR
Z Kardiol; 1997 Aug; 86(8):581-91. PubMed ID: 9417748
[TBL] [Abstract][Full Text] [Related]
9. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
[TBL] [Abstract][Full Text] [Related]
10. Do fish oils prevent restenosis after coronary angioplasty?
Leaf A; Jorgensen MB; Jacobs AK; Cote G; Schoenfeld DA; Scheer J; Weiner BH; Slack JD; Kellett MA; Raizner AE
Circulation; 1994 Nov; 90(5):2248-57. PubMed ID: 7955181
[TBL] [Abstract][Full Text] [Related]
11. First clinical experience with low molecular weight heparin LU 47311 (reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty.
Schmid KM; Preisack M; Voelker W; Sujatta M; Karsch KR
Semin Thromb Hemost; 1993; 19 Suppl 1():155-9. PubMed ID: 8395719
[TBL] [Abstract][Full Text] [Related]
12. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of fish oil supplements in preventing clinical evidence of restenosis after percutaneous transluminal coronary angioplasty.
Milner MR; Gallino RA; Leffingwell A; Pichard AD; Brooks-Robinson S; Rosenberg J; Little T; Lindsay J
Am J Cardiol; 1989 Aug; 64(5):294-9. PubMed ID: 2526993
[TBL] [Abstract][Full Text] [Related]
14. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
Circulation; 1992 Jul; 86(1):100-10. PubMed ID: 1535568
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty.
Gimple LW; Herrmann HC; Winniford M; Mammen E
Am J Cardiol; 1999 Jun; 83(11):1524-9. PubMed ID: 10363865
[TBL] [Abstract][Full Text] [Related]
16. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
Tsuchikane E; Fukuhara A; Kobayashi T; Kirino M; Yamasaki K; Kobayashi T; Izumi M; Otsuji S; Tateyama H; Sakurai M; Awata N
Circulation; 1999 Jul; 100(1):21-6. PubMed ID: 10393676
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
Serruys PW; Klein W; Tijssen JP; Rutsch W; Heyndrickx GR; Emanuelsson H; Ball SG; Decoster O; Schroeder E; Liberman H
Circulation; 1993 Oct; 88(4 Pt 1):1588-601. PubMed ID: 8403306
[TBL] [Abstract][Full Text] [Related]
18. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA).
DeMaio SJ; King SB; Lembo NJ; Roubin GS; Hearn JA; Bhagavan HN; Sgoutas DS
J Am Coll Nutr; 1992 Feb; 11(1):68-73. PubMed ID: 1541798
[TBL] [Abstract][Full Text] [Related]
19. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
Serruys PW; Foley DP; Jackson G; Bonnier H; Macaya C; Vrolix M; Branzi A; Shepherd J; Suryapranata H; de Feyter PJ; Melkert R; van Es GA; Pfister PJ
Eur Heart J; 1999 Jan; 20(1):58-69. PubMed ID: 10075142
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group.
Emanuelsson H; Beatt KJ; Bagger JP; Balcon R; Heikkilä J; Piessens J; Schaeffer M; Suryapranata H; Foegh M
Circulation; 1995 Mar; 91(6):1689-96. PubMed ID: 7882475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
